A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint
NCT ID: NCT00903565
Last Updated: 2019-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1200 participants
OBSERVATIONAL
2008-09-30
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Secondary objectives include comparing the objective risk assessment results from the prognostic profile (ColoPrint) to both the risk assessment based on the ASCO criteria, as well as the Investigator's independent assessment. As this is the first prospective study of ColoPrint, this study will also address the logistics and quality assurance of using ColoPrint in clinical practice.
Patient treatment is at the discretion of the physician, adhering to National Comprehensive Cancer Network (NCCN)-approved regimens or a recognized alternative.
The enrollment period will be 6 years. It is expected that 1800 to 2400 patients will be enrolled in order to obtain 785 analysable stage II samples from eligible patients. Approximately 25-35 clinical sites will be involved worldwide.
The statistical analysis will be performed by Agendia and an independent research institute or hospital.
Study Design Extension Study:
This will be a prospective study to measure the impact of ColoPrint on adjuvant treatment in stage 2 colorectal cancer patients. After surgery the tumor sample will be shipped in RNA Retain to Agendia. The online Clinical Report Form (CRF) 0 will be completed to document if the patient fulfils the inclusion criteria. Baseline clinical data and the patient and physician chemotherapy intention, patient's perceived recurrence risk and decisional conflict without knowing the ColoPrint result will be entered in CRF 1. After completion of CRF1 the ColoPrint result is released. CRF2 will be completed after the final treatment decision has been made.
This CRF will capture the patient and physician chemotherapy intention, patient's perceived recurrence risk and decisional conflict, impact of ColoPrint and the actual treatment the patient will receive. CRF3 will be completed 12 months after enrolment and will capture the patient status, patient's perceived recurrence risk and decisional conflict. CRF4 and 5 will be completed 3 and 5 years after surgery and will capture the patient status. A sample size of 210 stage 2 colon cancer patients is required to detect a 10% overall treatment change (5% significance and 90% power).
Reporting of the Results:
Blinded Study; The ColoPrint results will not be reported to the physician and/or patient at the time of enrolment. All samples will be stored in a freezer until 550-575 eligible stage II patients have been enrolled. Samples will then be analyzed in one batch in a blinded fashion from the clinical results.
Extension Study; The ColoPrint results will be reported to the physician and patient after CRF1 has been completed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Incidence, Risk Factor, Treatment and Overall Survival of Locoregionally Recurrent Colon Cancer
NCT05475288
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
NCT00843375
Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer Patients
NCT00354705
Relapse Markers for Colorectal Cancer
NCT04920955
Screening and Risk Factors of Colon Neoplasia
NCT01647776
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Secondary Objectives
• To assess the feasibility of using the ColoPrint test in the clinical setting.
* To compare the risk assessment in stage II patients using the ColoPrint profile vs a clinical risk assessment based on 1) Investigator's assessment of risk and 2) ASCO high-risk recommendations (T4 lesions, perforation / obstruction, inadequate node sampling (less than 12 nodes) or poorly differentiated histology).
* To establish the proportion of low-risk and high-risk ColoPrint profiles in stage II colorectal cancer patients in various countries.
* To investigate therapy as a potential confounding factor for ColoPrint results.
* To assess the performance of ColoPrint in estimating the 3-year relapse rate in patients with stage III colorectal cancer.
* To compare the performance of ColoPrint vs the clinical risk assessment in estimating the 5-year relapse rate.
* Assess the impact of ColoPrint on adjuvant chemotherapy treatment decisions in stage 2 colorectal cancer patients
* Compare the ColoPrint results from fresh RNARetain colorectal tumor specimens to the matched formalin-fixed paraffin-embedded tissue (FFPE) colon tumor specimens for concordance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* adenocarcinoma of the colon or rectum
* stage II-III, planned to be treated with radical surgery
Exclusion Criteria
* any neo-adjuvant therapy
* synchronous tumors
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Agendia
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ramon Salazar, MD
Role: PRINCIPAL_INVESTIGATOR
Institut Català D´Oncologia, L'Hospitalet Barcelona
John L Marshall, MD
Role: PRINCIPAL_INVESTIGATOR
Chief, Division of Hematology/Oncology, Georgetown University Hospital Washington
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Glendale Memorial Hospital
Glendale, California, United States
South Orange County Surgical Medical Group
Laguna Hills, California, United States
Long Beach Memorial Medical Center
Long Beach, California, United States
Sutter Roseville Medical Center /Research
Roseville, California, United States
Sutter Cancer Center
Sacramento, California, United States
UC Davis Cancer Center
Sacramento, California, United States
Scripps Cancer Center
San Diego, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Yale Cancer Center
New Haven, Connecticut, United States
Georgetown University Hospital
Washington D.C., District of Columbia, United States
University of Miami
Miami, Florida, United States
Atlanta Colon and Rectal Surgery
Riverdale, Georgia, United States
Albert Einstein College of Medicine, Montefiore Medical Center
The Bronx, New York, United States
Wake Forest University
Winston-Salem, North Carolina, United States
Ohio State University
Columbus, Ohio, United States
MD Anderson Cancer Center
Houston, Texas, United States
Franciscan Research Center
Tacoma, Washington, United States
Landeskrankenhaus Feldkirch
Feldkirch, , Austria
Krankenhaus der Elisabethinen
Linz, , Austria
Medical University of Vienna
Vienna, , Austria
University of Hong Kong/ Queen Mary Hospital
Hong Kong, , China
Odense Universitetshospital
Odense, , Denmark
CRLC Val d'Aurelle-Paul Lamarque
Montpellier, , France
Klinikum Rechts Der Isar
Munich, , Germany
Matsuda Hospital
Hamamatsu, , Japan
Medisch Centrum Alkmaar
Alkmaar, , Netherlands
Medisch Spectrum Twente
Enschede, , Netherlands
Westfriesgasthuis
Hoorn, , Netherlands
LUMC
Leiden, , Netherlands
Vall d' Hebron University Hospital
Barcelona, , Spain
IDIBELL Institut Catala d'Oncologia (ICO)
L'Hospitalet de Llobregat, , Spain
Immunology Akademiska sjukhuset/ University Hospital
Uppsala, , Sweden
Kantonsspital Baden
Baden, , Switzerland
Norfolk and Norwich University Hospital
Norwich, , United Kingdom
University of Oxford
Oxford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CP-060-CR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.